{"id":"W3217126890","doi":"10.1200/jco.21.02229","title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1104,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"National Cancer Institute; EMD Serono; Genentech; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Amgen; Celldex Therapeutics; Array BioPharma; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Melanoma; Metastatic melanoma; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001462872,0.000381012,0.0008786551,0.0002106879,0.0003149183,0.0004977289,0.0002934766,0.0005482822,0.001411486],"category_scores_gemma":[0.001050559,0.0001360988,0.001240785,0.0001660326,0.0003389964,0.0004732285,0.000250312,0.00129132,0.0002759342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004839983,"about_ca_system_score_gemma":0.0004190403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000286169,"about_ca_topic_score_gemma":0.000793509,"domain_scores_codex":[0.9996543,0.0001426728,0.00002760111,0.00005726587,0.00004760197,0.0000706005],"domain_scores_gemma":[0.9991964,0.0001530339,0.0002247227,0.00004255068,0.0000404538,0.0003428046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6926301,0.01176916,0.1147434,0.0007893926,0.003857503,0.0004063276,0.0001950602,0.004567482,0.01463116,0.0001937631,0.003693044,0.1525237],"study_design_scores_gemma":[0.09144557,0.5618232,0.3283553,0.0002396356,0.003633594,0.000856765,0.0001438702,0.004232776,0.004309725,0.0006152577,0.004278771,0.00006559282],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948619,0.003873247,0.000144743,0.0002280234,0.00008948347,0.00006284539,0.0002203649,0.000009747335,0.0005094923],"genre_scores_gemma":[0.9978955,0.00065086,0.0001144421,0.0002508629,0.0001460591,0.00007198717,0.0004267212,0.000002150719,0.0004414348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001462872,"threshold_uncertainty_score":0.007736504,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07445865462662754,"score_gpt":0.4172274161971886,"score_spread":0.342768761570561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}